CONCORD, Calif.—Jensen Chrystal, Chief Legal Officer at Cerus Corp (NASDAQ:CERS), recently sold 16,667 shares of the company’s common stock. The transactions, executed under a 10b5-1 plan, occurred on December 16 at prices ranging from $1.675 to $1.735 per share, with a weighted average price of $1.71. The total value of the shares sold amounted to approximately $28,500.
Following these transactions, Chrystal retains direct ownership of 457,578 shares in Cerus Corp. While the company maintains a GOOD financial health score according to InvestingPro, investors should note it trades at a high Price/Book ratio of 6.25x. Discover more insights with InvestingPro's comprehensive research report, available for over 1,400 US stocks.
In other recent news, Cerus Corporation has reported substantial Q3 revenue growth of 16%, amounting to $46 million, mainly driven by its North American platelet business. The company also revised its full-year product revenue guidance upwards, citing positive trends in its INTERCEPT Fibrinogen Complex (IFC) business and increased production capacity. Furthermore, Cerus highlighted a $248 million contract with BARDA to advance the INTERCEPT Red Blood Cell (RBC) program, addressing public health concerns related to blood supply safety.
The company also announced the extension of their supply and manufacturing agreement with Porex Corporation. Under the agreement, Cerus has secured unit pricing for platelet wafers and plasma disks for the first two years of the contract. This contract extension aims to ensure the continued supply of key components for Cerus's products, which are integral to the company's operations.
In addition, Cerus Corporation plans to launch an LED illuminator in Europe in 2025 and in the U.S. in 2026. Growth is anticipated from new customer acquisitions and increased usage among existing clients. These are among the recent developments for Cerus Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.